The detailed analysis of immune markers within the tumor microenvironment, particularly the expressions of FOXP3, PD-1, and CD32B, offers valuable insights into their potential as prognostic biomarkers and therapeutic targets [36,37]. The gene discussed is FOXP3; the disease is neoplasm.